Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2007-2009

ABSTRACT

This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer. Detailed Description It is an open labelled, randomized, mono-center phase III clinical trail.A total of 250 patients with resected stage IB to stage IIIA non-small cell lung cancer will either the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus cisplatin randomly. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimens.The major inclusive criteria are pathological confirmed non-small cell lung cancer after complete resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked for further investigation. All of the enrolled patients will be followed up until death or over 5 years. More... »

URL

https://clinicaltrials.gov/show/NCT01124253

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer.\n\nDetailed Description\nIt is an open labelled, randomized, mono-center phase III clinical trail.A total of 250 patients with resected stage IB to stage IIIA non-small cell lung cancer will either the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus cisplatin randomly. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimens.The major inclusive criteria are pathological confirmed non-small cell lung cancer after complete resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked for further investigation. All of the enrolled patients will be followed up until death or over 5 years.", 
    "endDate": "2009-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01124253", 
    "keywords": [
      "Phase III study", 
      "NPs", 
      "in-patient", 
      "non small cell lung cancer", 
      "vinorelbine", 
      "cisplatin", 
      "overall survival", 
      "patient", 
      "Phase III", 
      "Stage Ib", 
      "primary end point", 
      "Secondary end point", 
      "recurrence-free survival", 
      "toxicity", 
      "safety", 
      "regimen", 
      "criterion", 
      "complete resection", 
      "Drug Therapy", 
      "tissue", 
      "blood sample", 
      "enrolled patient", 
      "death"
    ], 
    "name": "Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01124253"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00008.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412524.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452927.f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.16821.3c", 
        "type": "Organization"
      }
    ], 
    "startDate": "2007-07-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1756-9966-31-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046843633", 
          "https://doi.org/10.1186/1756-9966-31-34"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01124253"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01124253'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01124253'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01124253'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01124253'


 

This table displays all metadata directly associated to this object as RDF triples.

50 TRIPLES      16 PREDICATES      41 URIs      32 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01124253 schema:about anzsrc-for:3142
2 schema:description This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer. Detailed Description It is an open labelled, randomized, mono-center phase III clinical trail.A total of 250 patients with resected stage IB to stage IIIA non-small cell lung cancer will either the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus cisplatin randomly. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimens.The major inclusive criteria are pathological confirmed non-small cell lung cancer after complete resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked for further investigation. All of the enrolled patients will be followed up until death or over 5 years.
3 schema:endDate 2009-10-01T00:00:00Z
4 schema:keywords Drug Therapy
5 NPs
6 Phase III
7 Phase III study
8 Secondary end point
9 Stage Ib
10 blood sample
11 cisplatin
12 complete resection
13 criterion
14 death
15 enrolled patient
16 in-patient
17 non small cell lung cancer
18 overall survival
19 patient
20 primary end point
21 recurrence-free survival
22 regimen
23 safety
24 tissue
25 toxicity
26 vinorelbine
27 schema:name Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
28 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01124253
29 schema:sdDatePublished 2019-03-07T15:23
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher Nee5f29d734344eb7b2a96d422287e283
32 schema:sponsor https://www.grid.ac/institutes/grid.16821.3c
33 https://www.grid.ac/institutes/grid.412524.4
34 https://www.grid.ac/institutes/grid.452927.f
35 schema:startDate 2007-07-01T00:00:00Z
36 schema:subjectOf sg:pub.10.1186/1756-9966-31-34
37 schema:url https://clinicaltrials.gov/show/NCT01124253
38 sgo:license sg:explorer/license/
39 sgo:sdDataset clinical_trials
40 rdf:type schema:MedicalStudy
41 Nee5f29d734344eb7b2a96d422287e283 schema:name Springer Nature - SN SciGraph project
42 rdf:type schema:Organization
43 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
44 rdf:type schema:DefinedTerm
45 sg:pub.10.1186/1756-9966-31-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046843633
46 https://doi.org/10.1186/1756-9966-31-34
47 rdf:type schema:CreativeWork
48 https://www.grid.ac/institutes/grid.16821.3c schema:Organization
49 https://www.grid.ac/institutes/grid.412524.4 schema:Organization
50 https://www.grid.ac/institutes/grid.452927.f schema:Organization
 




Preview window. Press ESC to close (or click here)


...